<DOC>
	<DOC>NCT01153971</DOC>
	<brief_summary>This study will evaluate the efficacy and safety of MabThera in combination chemotherapy, followed by maintenance treatment with MabThera. The anticipated time on study treatment is 1-2 years, and the target sample size is &lt;100 individuals.</brief_summary>
	<brief_title>A Study of Induction and Maintenance Treatment With MabThera (Rituximab) in Patients With Indolent B-Cell Nonfollicular Lymphomas</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>adult patients 1865 years of age; previously untreated indolent nonfollicular nonHodgkin's lymphoma; active disease; &gt;=3 involved sites. typical chronic lymphocytic leukemia; other malignancies within 3 years before study, except basal or squamous cell skin cancer or cancer in situ of the cervix; systemic corticosteroid use for &gt;1 month; significant cardiovascular disease; central nervous system involvement; hepatitis B or C virus infection, or HIV infection.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>